Pfizer to request emergency use of its COVID-19 vaccine project

Pfizer has already collected the safety data required by health authorities to approve its COVID-19 vaccine for emergency use

The American Pharmacist Pfizer is preparing to apply imminently for the emergency approval from his COVID-19 vaccine, which has already exceeded the security requirements set for its phase 3 trials, according to the company’s CEO, Albert Bourla, on Tuesday.

Bourla spoke this way in a forum organized by The New York Times and in another of the specialized health medium STAT News, after his company and his partner BioNTech announced on November 9 that the vaccine is more than 90 percent effective.

“We are very close to requesting the emergency authorization,” said the chief executive of the pharmaceutical company, who did not want to give a precise date for that expected step.

Pfizer and BioNTech candidate vaccine against COVID-19. Photo from .

According to Bourla, Pfizer has already collected the safety data required by health authorities, which require manufacturers to follow up for two months of at least half of the people who received the vaccine during phase 3 trials.

In the tests, which began last July, about 44 thousand people have participated and, according to the companies, the vaccine has shown an effectiveness greater than 90 percent in the participants without previous evidence of infection.

Following the announcement of Pfizer Y BioNTech, this Monday the biotechnology Modern released test results for its vaccine project, which point to an effectiveness of around 94 percent.

Pfizer headquarters in Puurs, Belgium. Photo from .

Bourla, in the STAT News forum, assured that he was relieved to learn that there is another successful vaccine and was confident that there will be more, given that global demand will exceed the capacity of any company.

When they announced the success of their trials, Pfizer and BioNTech announced that they expect to produce 50 million doses this year and 1.3 billion doses in 2021.

With information from .